Patents by Inventor Frederic Ors

Frederic Ors has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
    Patent number: 12042537
    Abstract: The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 ?l and induces an antibody immune response to the B-cell epitope in the human subject.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: July 23, 2024
    Assignee: BioVaxys Inc.
    Inventors: Marc Mansour, Frederic Ors, Marianne Stanford, Leeladhar Sammatur, Rajkannan Rajagopalan, Lisa Diana MacDonald
  • Recombinant influenza virus-like particles (VLPS) produced in transgenic plants
    Patent number: 11434497
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: September 6, 2022
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
  • Methods of using low dose volume B-cell epitope compositions for inducing an antibody immune response in human subjects
    Patent number: 11406705
    Abstract: The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 ?l and induces an antibody immune response to the B-cell epitope in the human subject.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: August 9, 2022
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marc Mansour, Frederic Ors, Marianne Stanford, Leeladhar Sammatur, Rajkannan Rajagopalan, Lisa Diana MacDonald
  • Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
    Patent number: 11260116
    Abstract: The present application relates to vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier. Further described are methods and use of the vaccine composition for inducing an antibody immune response and/or a cell-mediated immune response to the neoantigen, as well as methods and uses of the vaccine compositions in the treatment of cancer.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: March 1, 2022
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marianne Stanford, Genevieve Weir, Frederic Ors, Leeladhar Sammatur
  • Methods of Using Low Dose Volume B-cell Epitope Compositions for Inducing an Antibody Immune Response in Human Subjects
    Publication number: 20190224312
    Abstract: The present disclosure provides methods, uses and compositions and kits for use in inducing an antibody immune response in a human subject. The methods and uses involve administering parenterally a low dose volume of a composition comprising an antigen comprising a B-cell epitope, an amphipathic compound, and a hydrophobic carrier, wherein the low dose volume of the composition is less than 100 ?l and induces an antibody immune response to the B-cell epitope in the human subject.
    Type: Application
    Filed: September 27, 2016
    Publication date: July 25, 2019
    Applicant: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marc Mansour, Frederic Ors, Marianne Stanford, Leeladhar SAMMATUR, Rajkannan Rajagopalan, Lisa Diana MACDONALD
  • Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
    Patent number: 10190132
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: January 29, 2019
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
  • Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
    Patent number: 9458470
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: October 4, 2016
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
  • Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant
    Patent number: 9452210
    Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: September 27, 2016
    Assignee: MEDICAGO INC.
    Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trépanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vézina, Nathalie Landry